School of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.
Traditional Chinese Medicine Research Institute, Tai'an Hospital of Chinese Medicine, Tai'an 271000, China.
Comput Math Methods Med. 2022 Aug 4;2022:2556521. doi: 10.1155/2022/2556521. eCollection 2022.
Modified Sanmiaosan is an effective cure in the treatment of ulcerative colitis, but its mechanisms of action remain unclear. This study revealed the pharmacological mechanisms of Modified Sanmiaosan acting on ulcerative colitis through a pharmacology approach.
The active compounds and the targets of Modified Sanmiaosan were selected from the Traditional Chinese Medicine Systems Pharmacology database according to the absorption and metabolism. The UC-related therapeutic targets were collected from the PharmGKB database, the GeneCards database, the GADA database, and the OMIM database. The networks of "drug-component-target-disease" and "herbal-component-target" were constructed by the Cytoscape software. Protein-protein interaction network was generated by the STRING database. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed by the R software. Molecular docking technology was used to identify the affinity and activity between active compounds and targets.
The 80 effective ingredients of MSM were collected. A total of 5180 UC-related genes and the 153 key targets of MSM and UC-related were obtained. JUN, Akt1, and MAPK1 were identified as the "hub targets" involved in the effects of Modified Sanmiaosan on ulcerative colitis. Hub targets were mainly involved in inflammatory response and oxidative stress. As the results of GO analysis, biological processes such as DNA-binding transcription and RNA polymerization may participate in the treatment process; KEGG pathway analysis showed that hub targets were mainly involved in IL-17 signal pathway and TNF signal pathway of ulcerative colitis. The high affinity and activity of the active compounds and targets were verified through molecular docking.
These findings demonstrate the active ingredients in Modified Sanmiaosan reduce inflammatory response by TNF and IL-17 signaling pathways to treat ulcerative colitis. Anti-inflammation and immune regulation may be the main mechanism of Modified Sanmiaosan in the treatment of ulcerative colitis. This study not only provide new insights into the development of a natural therapy for the prevention and treatment of ulcerative colitis but also proves a feasible method for discovering potential activated compounds from Chinese herbs.
改良三妙散是治疗溃疡性结肠炎的有效方剂,但作用机制尚不清楚。本研究采用药理学方法揭示改良三妙散治疗溃疡性结肠炎的药理机制。
根据吸收和代谢情况,从中药系统药理学数据库中筛选出改良三妙散的活性成分和作用靶点;从 PharmGKB 数据库、GeneCards 数据库、GADA 数据库和 OMIM 数据库中收集与 UC 相关的治疗靶点;采用 Cytoscape 软件构建“药物-成分-靶点-疾病”和“草药-成分-靶点”网络;采用 STRING 数据库构建蛋白质-蛋白质相互作用网络;采用 R 软件进行基因本体(GO)和京都基因与基因组百科全书(KEGG)通路富集分析;采用分子对接技术鉴定活性成分与靶点之间的亲和力和活性。
共收集到 MSM 的 80 种有效成分,获得 5180 个 UC 相关基因和 MSM 与 UC 相关的 153 个关键靶点。JUN、Akt1 和 MAPK1 被鉴定为参与改良三妙散治疗溃疡性结肠炎的“枢纽靶点”。枢纽靶点主要涉及炎症反应和氧化应激。GO 分析结果表明,DNA 结合转录和 RNA 聚合等生物过程可能参与治疗过程;KEGG 通路分析表明,枢纽靶点主要参与溃疡性结肠炎的 IL-17 信号通路和 TNF 信号通路。通过分子对接验证了活性成分和靶点之间的高亲和力和高活性。
这些发现表明,改良三妙散中的活性成分通过 TNF 和 IL-17 信号通路减轻炎症反应,从而治疗溃疡性结肠炎。抗炎和免疫调节可能是改良三妙散治疗溃疡性结肠炎的主要机制。本研究不仅为开发天然疗法防治溃疡性结肠炎提供了新的思路,也为从中药中发现潜在的激活化合物提供了可行的方法。